Local News

• Johnson & Johnson extends tender offer for Mentor Corporation  Johnson & Johnson announced it has extended its previously announced cash tender offer, through its wholly owned subsidiary, Maple Merger Sub, for all outstanding shares of common stock of Mentor Corporation until 5:00 p.m. (Eastern time), on January 16, 2009, unless further extended.
  Johnson & Johnson January 06, 2009  
• Accelrys announces resignation of CEO and appointment of interim CEO  Accelrys reported that Mark Emkjer, its President and Chief Executive Officer has resigned as an officer and director of the company, effective January 5, 2009. Mr. Emkjer will remain employed by the Company until February 1, 2009 to assist in transitioning his role and responsibilities.
  Accelrys, Inc. January 06, 2009  
• Monsanto announces yield gains with Deltapine Class Of 09  Monsanto Company announced its D&PL business will market five new varieties as the Deltapine Class of 09 for the coming production season. These varieties were introduced during the 2009 Beltwide Cotton Conferences that have brought the cotton industry together in San Antonio.
  Monsanto Company January 06, 2009  
• BioMarin and La Jolla Pharmaceutical sign development and commercialization agreement  BioMarin Pharmaceutical and La Jolla Pharmaceutical announced that they have entered into an agreement to develop and commercialize Riquent(R), La Jolla's investigational drug for lupus nephritis, in the U.S., Europe and all other territories of the world, excluding the Asia Pacific region.
  BioMarin Pharmaceutical Inc. January 06, 2009  
• Onyx acquires option to license novel highly specific JAK2 inhibitors from S*BIO  Onyx Pharmaceuticals announced that it has acquired an option to license rights to SB1518, an orally available, potent, and selective inhibitor of Janus Kinase 2 (JAK2), and SB1578, also a JAK2 inhibitor, from S*BIO Pte Ltd based in Singapore.
  Onyx Pharmaceuticals, Inc. January 06, 2009  
• Abbott completes acquisition of Ibis Biosciences, a subsidiary of Isis  Isis Pharmaceuticals and Abbott announced that Abbott has completed its purchase of Ibis Biosciences, an Isis subsidiary, for a closing purchase price of $175 million.
  Isis Pharmaceuticals, Inc. January 06, 2009  
• CytRx announces management promotion  CytRx announced the appointment of John C. Caloz to the position of Chief Financial Officer. Former Chief Financial Officer Mitchell Fogelman resigned December 31, 2008, for personal reasons.
  CytRx Corporation January 06, 2009  
• Halozyme receives $5.5 million payment from Baxter  Halozyme Therapeutics announced receipt of $5.5 million from Baxter Healthcare Corporation representing the final prepaid product-based payment due under the terms of its HYLENEX licensing agreement, which provides Baxter with exclusive distribution rights.
  Halozyme Therapeutics, Inc. January 06, 2009  
• Cytori expands patent protection for Celution Stem & Regenerative Cell Processing System  Cytori received U.S. Patent No. 7,473,420, which protects important formulations of the Celution(R) System output. This builds upon U.S. Patent No. 7,390,484 which covers the Celution System technology for the bedside processing of stem and regenerative cells derived from adipose tissue.
  Cytori Therapeutics January 06, 2009  
• PDL BioPharma announces conversion rate adjustment for its 2.00% Convertible Senior Notes  PDL BioPharma announced the adjustment to the conversion rate for its 2.00% Convertible Senior Notes due February 15, 2012 (Notes). The conversion rate, as adjusted, is 82.162 shares of common stock per $1,000 principal amount of the Notes, effective January 5, 2009.
  PDL BioPharma January 06, 2009  

   (next 10 articles)